We are live on ! Find out more
SENS icon

Senseonics Holdings Inc

9.63 USD
-0.27
2.73%
At close Updated Sep 4, 4:00 PM EDT
Pre-market
After hours
9.58
-0.05
0.52%
1 day
-2.73%
5 days
3.66%
1 month
78.33%
3 months
37.38%
6 months
40.17%
Year to date
63.5%
1 year
7.48%
5 years
-87.59%
10 years
-88.11%
 

About: Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Employees: 130

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 28.6%
Neutral 57.1%
Negative 14.3%
Neutral
MarketBeat
1 month ago
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights
Neutral
Seeking Alpha
1 month ago
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q2 2026 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.4 per share a year ago.
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., July 21, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, August 6, 2026.
Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
Positive
Zacks Investment Research
2 months ago
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Positive
Zacks Investment Research
2 months ago
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
SENS partners with Welldoc on a next-gen Eversense 365 app, adding Apple Health/Google Health Connect integration ahead of the U.S. launch.
Senseonics Expands Eversense 365 Ecosystem With Welldoc Partnership
Neutral
Seeking Alpha
3 months ago
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Neutral
GlobeNewsWire
3 months ago
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8 in New Orleans, Louisiana.
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
Neutral
MarketBeat
4 months ago
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Neutral
Seeking Alpha
4 months ago
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Senseonics Holdings, Inc. (SENS) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™